News

Sarepta extends losses premarket after refusing FDA’s halt request

Sarepta Therapeutics (NASDAQ:SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a ...
The Manila Times6h

Transaction in Own Shares

In accordance with Article 5 (1) (b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), (as in force in the UK and as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019), ...